SCHEMBL4674741

SCHEMBL4674741

O=C(C=C(O)c1nn[nH]n1)c1cccn1S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPME1 Q9Y570 2/20 0.38
RORC P51449 2/20 0.36
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA9 Q16790 2/20 0.33
ALDH3A1 P30838 1/20 0.33
PKM P14618 1/20 0.32
MMP3 P08254 2/20 0.32
MMP8 P22894 2/20 0.32
HTR6 P50406 1/20 0.32
AKR1C3 P42330 1/20 0.31
GPR183 P32249 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672248 0.90 RAPGEF4 (0.39) PPME1CA2CA9ALDH3A1PKM
SCHEMBL4678991 0.85 RORC (0.33) RORCAKR1C3KMT2AHDAC3HDAC4
SCHEMBL4671824 0.83 PPME1 (0.38) PPME1RORCCA12CA1CA2
SCHEMBL4674175 0.82 PTGDR2 (0.34) RORCALDH3A1MMP3MMP8KMT2A
SCHEMBL4674323 0.81 KMT2A (0.33) RORCAKR1C3KMT2A
SCHEMBL4673793 0.81 CES1 (0.38) ALDH3A1PKMHTR6MEN1KMT2A
SCHEMBL4676526 0.81 KMT2A (0.32) RORCMMP3MMP8AKR1C3KMT2A
SCHEMBL4674859 0.81 NOD2 (0.35) RORC
SCHEMBL4672034 0.80 PTGDR2 (0.34) ALDH3A1MMP3MMP8KMT2A
SCHEMBL4672120 0.79 PKM (0.39) RORCPKMAKR1C3KMT2AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 PPME1 2162/4885RORC 230/4885CA12 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.